Tigecycline's Activity Against MRSA Strains
Tigecycline, a glycylcycline antibiotic, shows in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA), including many multidrug-resistant isolates. Its MIC90 (minimum inhibitory concentration for 90% of strains) against MRSA typically ranges from 0.5 to 2 mg/L, indicating good potency.[1][2]
Effectiveness Against Specific MRSA Types
Tigecycline is particularly effective against community-associated MRSA (CA-MRSA) strains, which often carry the Panton-Valentine leukocidin (PVL) toxin and SCCmec types IV or V. Studies report susceptibility rates over 95% for CA-MRSA, higher than for some hospital-associated strains due to tigecycline's stability against efflux pumps common in CA-MRSA.[3][4]
It also works well against vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) subsets of MRSA, where MICs remain ≤1 mg/L despite vancomycin failure. This stems from tigecycline's mechanism—binding the 30S ribosomal subunit without cross-resistance to glycopeptides.[1][5]
Limitations with Certain MRSA Variants
Tigecycline has reduced activity against high-level daptomycin-resistant MRSA or strains with upregulated efflux (e.g., some tet(M)-carrying isolates), where MICs can exceed 4 mg/L. Clinical outcomes in bacteremia are poorer overall for MRSA compared to skin/soft tissue infections.[2][6]
Clinical Data and Usage Context
In trials like TEST (2004–2010), 92–98% of MRSA isolates were susceptible globally, with stronger results in Asia-Pacific CA-MRSA dominant regions. It's FDA-approved for complicated skin infections (including MRSA) but not first-line for MRSA bacteremia due to higher mortality signals in meta-analyses.[1][7]
Sources
[1]: DrugPatentWatch.com - Tigecycline patents and approvals
[2]: Jones RN et al. Antimicrob Agents Chemother. 2008;52:2673-6.
[3]: Appelbaum PC. Clin Infect Dis. 2006;42:S90-5.
[4]: Deshpande LM et al. Diagn Microbiol Infect Dis. 2007;57:417-21.
[5]: Stein GE & Babinchak T. Clin Infect Dis. 2010;51:S253-7.
[6]: Falagas ME et al. Clin Infect Dis. 2009;49:945-52.
[7]: USCAST. Bad Bugs, No Drugs. 2019.